Welcome to our dedicated page for ORAMED PHARMACEUTICALS SEC filings (Ticker: ORMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oramed Pharmaceuticals Inc. reports material events and financial information through SEC filings that document its oral drug delivery business, investment-related agreements, and capital actions. Recent 8-K disclosures cover operating and financial results, option and warrant-related arrangements, payments tied to strategic investments, cash dividends, and material definitive agreements involving company assets and subsidiaries.
The filings also document Oramed’s common stock registration on the Nasdaq Capital Market and Tel Aviv Stock Exchange, its shareholder rights agreement, board-authorized distributions, and other capital-structure and governance matters. These records connect the company’s clinical-stage POD technology platform and oral insulin program with formal disclosures on liquidity, securities, contractual rights, and corporate events.
ORAMED PHARMACEUTICALS INC. (ORMP) held its 2026 Annual Meeting of Stockholders on September 15, 2026. Stockholders re‑elected all six directors standing for election. They also ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the 2026 fiscal year.
Stockholders approved an amendment to the Amended and Restated 2019 Stock Incentive Plan to increase the shares of common stock authorized for issuance under the plan by 3,000,000, to a total of 12,500,000 shares. On a non‑advisory basis, stockholders approved the compensation of named executive officers and selected a three‑year frequency for future say‑on‑pay votes. The board determined that say‑on‑pay votes will be held every three years. An adjournment proposal was rendered moot because all other proposals received sufficient support.
Aquamarine Financial (Cayman) Ltd reports beneficial ownership of 2,512,175 shares of Oramed Pharmaceuticals Inc. common stock, representing 6.04% of the class as of June 30, 2026. Aquamarine holds sole voting and sole dispositive power over all reported shares and no shared power.
Oramed Pharmaceuticals reported results for the six months ended June 30, 2026, after transforming into a strategic healthcare holding and operating company with no direct revenue-generating operations. Total assets rose to $369.6M from $230.9M, driven mainly by investment gains.
The company recorded a net income of $116.5M for the first half of 2026 and $78.2M for the quarter, largely from fair value increases in investments, especially its Alpha Tau stake and related warrants, which together were valued at about $211.3M. Core operations generated an operating loss of $6.4M, with R&D and G&A expenses totaling $6.4M.
Following the Lifeward transaction, Oramed transferred its POD oral insulin technology into OraTech, received Lifeward equity, warrants, convertible notes and a revenue-sharing right, and no longer conducts clinical development directly. Cash and cash equivalents declined to $15.2M, reflecting investment activity, a $0.25 per share special dividend (about $10.9M including equivalents), and tax withholdings on stock-based awards. The balance sheet now emphasizes concentrated financial investments, including Scilex notes subject to extension arrangements and high discount rates, and several real-estate–linked and private fund positions.
Oramed Pharmaceuticals Inc. is asking stockholders to vote at its 2026 annual meeting on six main items: electing six directors for one-year terms, ratifying Kesselman & Kesselman (a PwC member firm) as auditor for 2026, approving an amendment to the Long-Term Incentive Plan, advisory Say on Pay and Say on Frequency votes, and a potential adjournment authority.
The incentive plan amendment would increase the shares of common stock authorized for issuance under the plan by 3,000,000, bringing the total to 12,500,000. The meeting is set for September 15, 2026, in Jerusalem, with a record date of July 20, 2026, when 41,597,354 shares of common stock were outstanding and entitled to vote. A significant related-party transaction with Lifeward Ltd. transferred Oramed’s POD technology into OraTech and, at closing, yielded Oramed 1,250,363 Lifeward ordinary shares, multiple warrant positions and $9.0 million of senior secured convertible notes, with an option for an additional $9.0 million of notes upon milestones.
Oramed Pharmaceuticals COO & CBO Joshua Hexter reported an option exercise and share sale in the company’s stock. On July 2, 2026, he exercised 50,000 stock options at $3.69 per share, receiving an equal number of common shares. On July 1, 2026, he sold 137,000 common shares at a weighted average price of $4.463 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly holds 1,073,384 common shares and 50,000 stock options that remain outstanding.
ORAMED PHARMACEUTICALS INC. Chief Financial Officer Avraham Gabay reported an open-market sale of 73,360 shares of common stock on July 1, 2026 at a weighted average price of $4.5085 per share. The transaction was executed as a planned sale under a Rule 10b5-1 trading plan adopted on March 30, 2026, indicating it was pre-arranged rather than timed discretionarily. Following this sale, Gabay directly holds 671,785 shares, showing he retains a substantial equity position in the company.
Oramed Pharmaceuticals submitted a Form 144 disclosing proposed sales of common stock. The filing lists 137,000 shares alongside a $658,970.00 value and a larger share figure 40,926,081 dated 07/01/2026. It also records 108,000 shares issued upon RSU vesting on 05/01/2023 and 50,000 shares acquired on 07/01/2026 upon option exercise.
Oramed Pharmaceuticals Inc. submitted a Form 144 concerning Common Stock. The filing lists 93,360 shares tied to shares issued upon vesting of RSUs on 06/18/2026, notes Nasdaq as the market, and shows an associated date of 07/01/2026.
The filing text states the shares were issued with “No consideration, shares issued upon vesting of RSUs.” The notice appears procedural and lists header values including 449,061.60 and 40,926,081 in the securities section.
Oramed Pharmaceuticals Inc. updated its corporate bylaws and restructured payment timing on large notes owed by Scilex Holding Company. The board approved Fifth Amended and Restated Bylaws, which adjust how record dates and written stockholder consents are set and delivered.
Separately, Oramed agreed to extend repayment of Scilex’s Obligations under a Senior Secured Promissory Note and a Senior Secured Convertible Note, totaling about $29.5 million on the Tranche A Note and about $6.7 million on the Tranche B Note. Scilex will pay $0.5 million received on June 25, 2026, $5 million by July 31, 2026, and the remaining balance by September 30, 2026, with a mechanism that can recharacterize $1.5 million as an extension fee if full repayment is not made, and a provision to settle remaining amounts in registered common stock of Scilex or an affiliate.